Cost-effectiveness of artificial intelligence aided vessel occlusion detection in acute stroke: an early health technology assessment

Insights into Imaging

Table 4 Potential change in costs and QALYs when applying AI tool as opposed to usual care

% LVOs missed usual care	% of missed LVOs detected by innovation
% LVOs missed usual care	1%	25%	50%	75%	100%
1%	− 1$ + 0.00003 QALY	− 16$ + 0.0008 QALY	− 33$ + 0.0016 QALY	− 49$ + 0.0024 QALY	− 65$ + 0.0032 QALY
3%	− 2$ + 0.0001 QALY	− 49$ + 0.0024 QALY	− 98$ + 0.0048 QALY	− 147$ + 0.0071 QALY	− 196$ + 0.0095 QALY
6%	− 4$ + 0.0002 QALY	− 98$ + 0.0048 QALY	− 196$ + 0.0095 QALY	− 294$ + 0.0143 QALY	− 392$ + 0.0190 QALY
10%	− 7$ + 0.0003 QALY	− 163$ + 0.0791 QALY	− 327$ + 0.0158 QALY	− 490$ + 0.0237 QALY	− 654$ + 0.0317 QALY
20%	− 13$ + 0.0006 QALY	− 327$ + 0.0158 QALY	− 654$ + 0.0317 QALY	− 981$ + 0.0475 QALY	− 1,307$ + 0.0633 QALY

Costs and QALYs are per patient receiving CTA with indication stroke, when applying AI tool as opposed to usual care with varying ratio of missed LVOs in current care and varying rates of reduction in missed LVOs due to innovation. No costs for the AI innovation were included in this analysis
QALY, quality-adjusted life-year
Costs are rounded to the nearest integer